Compare KLA Corp. (KLAC) vs Summit Therapeutics Inc (SMMT) Price & Performance

KLA Corporation (KLAC) trades at $207.82, down 2.32% amid a semiconductor sector correction. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected, and robust profitability with a 35.66% net margin. Technical indicators signal bearish momentum with key support at $200, while analyst consensus remains bullish with a $243.43 price target. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid June 2, 2026.

KLAC's outlook is supported by dominant market positioning in semiconductor process control and AI-driven demand, but high valuation multiples (P/E 60.25) and sector volatility present risks. The stock offers growth potential through semiconductor equipment expansion, though investors should monitor industry cyclicality and competitive pressures from peers like Applied Materials.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.

The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.